Last reviewed · How we verify
Placebo matched to fenebrutinib — Competitive Intelligence Brief
phase 3
Placebo (matched to BTK inhibitor)
Immunology
Small molecule
Live · refreshed every 30 min
Target snapshot
Placebo matched to fenebrutinib (Placebo matched to fenebrutinib) — Hoffmann-La Roche. This is a placebo control arm matched to fenebrutinib, a Bruton's tyrosine kinase (BTK) inhibitor that blocks B-cell and myeloid cell activation.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Placebo matched to fenebrutinib TARGET | Placebo matched to fenebrutinib | Hoffmann-La Roche | phase 3 | Placebo (matched to BTK inhibitor) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Placebo (matched to BTK inhibitor) class)
- Hoffmann-La Roche · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Placebo matched to fenebrutinib CI watch — RSS
- Placebo matched to fenebrutinib CI watch — Atom
- Placebo matched to fenebrutinib CI watch — JSON
- Placebo matched to fenebrutinib alone — RSS
- Whole Placebo (matched to BTK inhibitor) class — RSS
Cite this brief
Drug Landscape (2026). Placebo matched to fenebrutinib — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-matched-to-fenebrutinib. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab